CTLA4 and melanoma: Other clinical characteristics such as primary melanoma subtype and treatment (single‐agent anti‐PD‐1 vs combination anti‐CTLA‐4 plus anti‐PD‐1) were not significantly associated with OS in this subset of patients (Supplementary figure 4b and c, Supplementary tables 2–5).